Orikine Bio focuses on discovering, researching, and developing precision-engineered bi-specific cytokine drugs for autoimmune and inflammatory disorders. Its proprietary FoldikineTM platform re-designs natural cytokines into optimized, dual-acting proteins called Foldikines that can more precisely modulate immune responses. The lead candidate, FoldikineTM ORK-1, targets autoimmune and inflammatory diseases and is currently in preclinical development. Orikine plans to use fresh capital to establish preclinical proof-of-concept data for ORK-1, a key step toward future clinical trials. Beyond ORK-1, the company intends to expand its pipeline to address additional autoimmune, inflammatory, and oncology indications. No revenue or user metrics have been disclosed, reflecting the company’s early R&D stage. Financially, Orikine Bio relies on innovation grants and research funding to progress its platform and pipeline.

Total raised

$7M

Funding rounds

2

Latest round

Equity

Latest activity

Dec 2024